NIH R01 · 2024
Abstract Adenoid Cystic Carcinoma (ACC) is a common salivary gland cancer for which there is no standard systemic therapy. ACC has a heterogeneous behavior; while most patients have an indolent disease course, approximately 30% have a very aggressive disease. There are currently no standard markers to prognosticate or for selecting treatment. Epigenetic changes are tightly linked to tumorigenesis and cancer progression and numerous studies imply that DNA methylation may serve as a valuable biomarker to identify molecular disease subtypes. However, studies evaluating whole ACC methylome and the evolutionary trajectories of methylation during the initiation and progression of ACC are lacking.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.